clinical trial · NCT00092040
A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)
Organon and Co·phase3·completed·n = 936
Osteoporosis, PostmenopausalMK0217, alendronate sodium/Duration of Intervention: 12 moComparator: risedronate / Duration of Intervention: 12 mo
brief summary
The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.
started
Mar 18, 2003
primary completion
Oct 18, 2004
completion
Sep 28, 2005
last updated
Aug 14, 2024
official title
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol